WO2008019417A3 - Traitement de maladies oculaires - Google Patents

Traitement de maladies oculaires Download PDF

Info

Publication number
WO2008019417A3
WO2008019417A3 PCT/AT2007/000393 AT2007000393W WO2008019417A3 WO 2008019417 A3 WO2008019417 A3 WO 2008019417A3 AT 2007000393 W AT2007000393 W AT 2007000393W WO 2008019417 A3 WO2008019417 A3 WO 2008019417A3
Authority
WO
WIPO (PCT)
Prior art keywords
neovascularisation
treatment
ocular diseases
protease
group
Prior art date
Application number
PCT/AT2007/000393
Other languages
English (en)
Other versions
WO2008019417A2 (fr
Inventor
Ahmed Aftab
Lucia Desser
Bernhard Lotz
Thomas Mohr
Original Assignee
Marlyn Nutraceuticals Inc
Ahmed Aftab
Lucia Desser
Bernhard Lotz
Thomas Mohr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marlyn Nutraceuticals Inc, Ahmed Aftab, Lucia Desser, Bernhard Lotz, Thomas Mohr filed Critical Marlyn Nutraceuticals Inc
Priority to RU2009109358/15A priority Critical patent/RU2472523C2/ru
Priority to JP2009524045A priority patent/JP2010500382A/ja
Priority to CA002658564A priority patent/CA2658564A1/fr
Priority to ES07784622.8T priority patent/ES2628813T3/es
Priority to EP07784622.8A priority patent/EP2056863B1/fr
Priority to DK07784622.8T priority patent/DK2056863T3/en
Priority to SI200731943T priority patent/SI2056863T1/sl
Priority to US12/377,556 priority patent/US9795656B2/en
Priority to MX2009001745A priority patent/MX2009001745A/es
Publication of WO2008019417A2 publication Critical patent/WO2008019417A2/fr
Publication of WO2008019417A3 publication Critical patent/WO2008019417A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins une protéase pour la fabrication d'un médicament destiné au traitement et/ou à la prévention de maladies oculaires associées à une néoangiogenèse et choisies parmi une dégénérescence maculaire liée à l'âge (DMLA), une néovascularisation choroïdienne, la maladie de Von Hippel-Lindau, une néovascularisation de l'iris, une rétinopathie ischémique proliférante, une néovascularisation de la cornée, et une rétinopathie drépanocytaire proliférante, ladite ou lesdites protéases étant choisies parmi des protéases de végétaux, d'animaux non mammaliens et de microbes.
PCT/AT2007/000393 2006-08-16 2007-08-16 Traitement de maladies oculaires WO2008019417A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2009109358/15A RU2472523C2 (ru) 2006-08-16 2007-08-16 Лечение глазных болезней
JP2009524045A JP2010500382A (ja) 2006-08-16 2007-08-16 眼疾患の治療
CA002658564A CA2658564A1 (fr) 2006-08-16 2007-08-16 Traitement de maladies oculaires
ES07784622.8T ES2628813T3 (es) 2006-08-16 2007-08-16 Tratamiento de enfermedades oculares
EP07784622.8A EP2056863B1 (fr) 2006-08-16 2007-08-16 Traitement de maladies oculaires
DK07784622.8T DK2056863T3 (en) 2006-08-16 2007-08-16 TREATMENT OF OCULAR DISEASES
SI200731943T SI2056863T1 (sl) 2006-08-16 2007-08-16 Zdravljenje očesnih bolezni
US12/377,556 US9795656B2 (en) 2006-08-16 2007-08-16 Treatment of ocular diseases
MX2009001745A MX2009001745A (es) 2006-08-16 2007-08-16 Tratamiento de enfermedades oculares.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1376/2006 2006-08-16
AT0137606A AT504159A1 (de) 2006-08-16 2006-08-16 Verwendung von proteasen

Publications (2)

Publication Number Publication Date
WO2008019417A2 WO2008019417A2 (fr) 2008-02-21
WO2008019417A3 true WO2008019417A3 (fr) 2008-05-29

Family

ID=38677891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2007/000393 WO2008019417A2 (fr) 2006-08-16 2007-08-16 Traitement de maladies oculaires

Country Status (15)

Country Link
US (1) US9795656B2 (fr)
EP (1) EP2056863B1 (fr)
JP (1) JP2010500382A (fr)
CN (1) CN101505790A (fr)
AT (1) AT504159A1 (fr)
CA (1) CA2658564A1 (fr)
DK (1) DK2056863T3 (fr)
ES (1) ES2628813T3 (fr)
HU (1) HUE034862T2 (fr)
MX (1) MX2009001745A (fr)
PL (1) PL2056863T3 (fr)
PT (1) PT2056863T (fr)
RU (1) RU2472523C2 (fr)
SI (1) SI2056863T1 (fr)
WO (1) WO2008019417A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341925B1 (fr) * 2008-09-10 2014-11-26 PT. Dexa Medica Agent thrombolytique/ agent anti-thrombotique et son procédé de production
EP2504025A4 (fr) * 2009-11-23 2013-05-01 Stephen F Olmstead Compositions et méthodes comprenant une peptidase serratia destinées à l'inhibition et au traitement de biofilms liés à certaines pathologies
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
US20140154235A1 (en) 2011-05-12 2014-06-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
JP2015523330A (ja) 2012-05-11 2015-08-13 スミス アンド ネフュー インコーポレイテッド 細菌性バイオフィルムを除去するためのセアプローゼの使用
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITMI20130117A1 (it) * 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
US20140212405A1 (en) * 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
US11065310B2 (en) 2016-05-27 2021-07-20 Nattocat, LLC Compositions and methods for thromboembolism dissolution
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
EP3573622B1 (fr) 2017-01-30 2023-10-18 Smith & Nephew, Inc. Combinaison synergique du thermolysin et d'un agent antibactérien pour réduire ou éliminer des biofilms sur des surfaces
JP7429503B2 (ja) * 2019-06-24 2024-02-08 小林製薬株式会社 ナットウキナーゼを含む経口組成物
TW202202168A (zh) * 2020-07-07 2022-01-16 洪啟庭 用於改善玻璃體混濁的組成物及其應用
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058666A1 (fr) * 1997-06-20 1998-12-30 Mucos Pharma Gmbh & Co. Utilisation d'enzymes proteolytiques dans le traitement de l'uveite
WO1999060984A2 (fr) * 1998-05-22 1999-12-02 Entremed, Inc. Compositions et methodes d'inhibition de la proliferation cellulaire endotheliale et de regulation de l'angiogenese a l'aide de serine-proteases
WO2000001410A1 (fr) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Procedes permettant d'inhiber des maladies proliferatives par inhibition d'angiogenese a mediation tgf-beta
WO2002076496A1 (fr) * 2001-03-22 2002-10-03 Van Andel Institute Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese
WO2002089833A2 (fr) * 2001-05-05 2002-11-14 University Of Florida Procedes et compositions destines a prevenir l'angiogenese
US20040086537A1 (en) * 1998-08-20 2004-05-06 Jun Inoue Prophylactic or threapeutic composition for ocular circulation disorders
WO2005056784A1 (fr) * 2003-12-15 2005-06-23 Japan Science And Technology Agency Polypeptide inductible de l'insuline
WO2005100556A2 (fr) * 2004-04-12 2005-10-27 Catalyst Biosciences Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes
WO2006025276A1 (fr) * 2004-08-31 2006-03-09 Kumamoto University Remède/traitement préventif pour maladies ophthalmiques contenant de la nattokinase
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
TR199901703T2 (xx) * 1996-11-19 2000-07-21 G.D. Searle & Co. Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7559718B2 (en) * 1999-01-27 2009-07-14 Trimble Navigation Limited Transducer arrangement
EP1539222A1 (fr) * 2002-07-02 2005-06-15 The Regents Of The University Of California Traitement pour trouble oculaire
EP1633866A1 (fr) * 2003-06-18 2006-03-15 Direvo Biotech AG Nouvelles entites biologiques et leur utilisation pharmaceutique ou diagnostique
US7354569B2 (en) * 2003-07-11 2008-04-08 Colgate-Palmolive Company Chewable antiplaque confectionery dental composition
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
US20090285826A1 (en) * 2006-05-04 2009-11-19 Fovea Pharmaceuticals Sa Combination drugs comprising vegf inhibitor and serine proteases/thrombolytic compounds for treating neovascular disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058666A1 (fr) * 1997-06-20 1998-12-30 Mucos Pharma Gmbh & Co. Utilisation d'enzymes proteolytiques dans le traitement de l'uveite
WO1999060984A2 (fr) * 1998-05-22 1999-12-02 Entremed, Inc. Compositions et methodes d'inhibition de la proliferation cellulaire endotheliale et de regulation de l'angiogenese a l'aide de serine-proteases
WO2000001410A1 (fr) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Procedes permettant d'inhiber des maladies proliferatives par inhibition d'angiogenese a mediation tgf-beta
US20040086537A1 (en) * 1998-08-20 2004-05-06 Jun Inoue Prophylactic or threapeutic composition for ocular circulation disorders
WO2002076496A1 (fr) * 2001-03-22 2002-10-03 Van Andel Institute Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese
WO2002089833A2 (fr) * 2001-05-05 2002-11-14 University Of Florida Procedes et compositions destines a prevenir l'angiogenese
WO2005056784A1 (fr) * 2003-12-15 2005-06-23 Japan Science And Technology Agency Polypeptide inductible de l'insuline
WO2005100556A2 (fr) * 2004-04-12 2005-10-27 Catalyst Biosciences Clivage de vegf et de recepteur vegf par des proteases de types sauvage et mutantes
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
WO2006025276A1 (fr) * 2004-08-31 2006-03-09 Kumamoto University Remède/traitement préventif pour maladies ophthalmiques contenant de la nattokinase

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Complications of Diabetes Mellitus: Retinopathy", INTERNET ARTICLE, XP002473105, Retrieved from the Internet <URL:http://www.medscape.com/viewarticle/548776?rss> [retrieved on 20080314] *
ANONYMOUS: "How Enzyme Therapy Works", INTERNET ARTICLE, 7 July 2004 (2004-07-07), XP002460092, Retrieved from the Internet <URL:http://www.enzyme-therapy.at/contenido/pdf/How%20Enzyme%20Therapy%20works.pdf> [retrieved on 20071127] *
ANONYMOUS: "Neprinol", INTERNET ARTICLE, March 2006 (2006-03-01), XP002473103, Retrieved from the Internet <URL:http://fibromedica-health-solutions.tradenote.net/product/426014-Neprinol-AFD-500mg> [retrieved on 20080317] *
ANONYMOUS: "Neprinol", INTERNET ARTICLE, XP002473110, Retrieved from the Internet <URL:http://www.crohns-disease-probiotics.com/neprinol.html> [retrieved on 20080317] *
CHANG J-H ET AL: "CORNEAL NEOVASCULARIZATION", CURRENT OPINION IN OPHTHALMOLOGY, PHILADELPHIA, PA, US, vol. 12, no. 4, August 2001 (2001-08-01), pages 242 - 249, XP008014313, ISSN: 1040-8738 *
DATABASE WPI Week 200548, Derwent World Patents Index; AN 2005-479082, XP002472658 *
DATABASE WPI Week 200623, Derwent World Patents Index; AN 2006-221964, XP002472657 *
DESSER L ET AL: "Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 47 Suppl, July 2001 (2001-07-01), pages S10 - S15, XP008086039, ISSN: 0344-5704 *
DZIVITE I ET AL: "Regular intake of Wobenzym(R) may prevent late complications in diabetes mellitus", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, vol. 17, no. 2-4, 2001, pages 143 - 148, XP008086097, ISSN: 0255-9625 *
GRIFFIOEN A W ET AL: "Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.", PHARMACOLOGICAL REVIEWS JUN 2000, vol. 52, no. 2, June 2000 (2000-06-01), pages 237 - 268, XP002473104, ISSN: 0031-6997 *
LAUER D ET AL: "Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 47 Suppl, July 2001 (2001-07-01), pages S4 - S9, XP008086038, ISSN: 0344-5704 *
MAURER H R: "Bromelain: biochemistry, pharmacology and medical use", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 58, no. 9, August 2001 (2001-08-01), pages 1234 - 1245, XP002995539, ISSN: 1420-682X *
MAZZONE A ET AL: "Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trialversus placebo", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, CAMBRIDGE MEDICAL PUBLICATIONS LTD, GB, vol. 18, no. 5, September 1990 (1990-09-01), pages 379 - 388, XP008089114, ISSN: 0300-0605 *
STARKOW G L ET AL: "PAPAIN THERAPY OF EYE DISEASES", KLINISCHE MONATSBLAETTER FUER AUGENHEILKUNDE, FERDINAND ENKE VERLAG, STUTTGART, DE, vol. 159, no. 6, 1971, pages 755 - 769, XP008089296, ISSN: 0023-2165 *
STAUDER G: "PHARMACOLOGICAL EFFECTS OF ORAL ENZYME COMBINATIONS", CASOPIS LEKARU CESKYCH, CZECH MEDICAL SOCIETY, PRAGUE, CZ, vol. 134, no. 19, 1995, pages 620 - 624, XP000652595, ISSN: 0008-7335 *
TAKANO AKIOMI ET AL: "Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE MAY 2006, vol. 47, no. 5, May 2006 (2006-05-01), pages 2075 - 2079, XP002472656, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
PT2056863T (pt) 2017-07-04
US20110311509A1 (en) 2011-12-22
WO2008019417A2 (fr) 2008-02-21
MX2009001745A (es) 2009-07-10
HUE034862T2 (en) 2018-03-28
RU2472523C2 (ru) 2013-01-20
AT504159A1 (de) 2008-03-15
CN101505790A (zh) 2009-08-12
RU2009109358A (ru) 2010-09-27
EP2056863B1 (fr) 2017-03-22
US9795656B2 (en) 2017-10-24
ES2628813T3 (es) 2017-08-04
PL2056863T3 (pl) 2017-11-30
EP2056863A2 (fr) 2009-05-13
DK2056863T3 (en) 2017-07-10
SI2056863T1 (sl) 2017-10-30
CA2658564A1 (fr) 2008-02-21
JP2010500382A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
WO2008019417A3 (fr) Traitement de maladies oculaires
WO2008140052A1 (fr) Agent prophylactique ou thérapeutique pour une maladie oculaire postérieure comprenant du ropinirole ou un sel de celui-ci comme ingrédient actif
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
WO2006071548A3 (fr) Analogues d&#39;aminopyrazine servant a traiter le glaucome et d&#39;autres maladies ou etats medies par rho kinase
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
Holland et al. Antibiotic resistance in acute postoperative endophthalmitis
WO2008111497A1 (fr) Agent prophylactique ou thérapeutique pour une maladie ophtalmique associée avec un stress oxydant, comprenant un triterpénoïde comme principe actif
DK1904056T3 (da) Anvendelse af et macrolid til at gendanne korneal fölelse
WO2010093945A3 (fr) Implant médicamenteux uvéoscléral et ses procédés d&#39;implantation
WO2007043052A3 (fr) Dispositif, systeme et procede pour dispositif ophtalmique a double trajet
WO2007044668A3 (fr) Compstatine et analogues de celle-ci pour des troubles de la vue
MX2010003774A (es) Formulaciones oftalmicas acuosas.
WO2007106381A3 (fr) Compositions ophtalmiques comprenant de la povidone iodée
TW200626721A (en) RNAi inhibition of CTGF for treatment of ocular disorders
BR112014008759A2 (pt) tratamento de doença ocular
WO2008067040A3 (fr) Procédé de détection de maladies et d&#39;affections pathologiques de l&#39;œil et traitement de celles-ci
WO2007075720A8 (fr) Preparations de mecamylamine topique pour administration oculaire et utilisations de celles-ci
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
WO2006119128A3 (fr) Ciblage vasculaire de neovascularisation oculaire
WO2006039252A3 (fr) Compositions et methodes de traitement de maladies ophtalmiques
WO2011151685A8 (fr) N-acétyl-dl-leucine, médicament neuroprotecteur et rétinoprotecteur
WO2007089673A8 (fr) Compositions et méthodes de traitement pour maladies et troubles ophtalmiques
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2007108920A3 (fr) Insert cornéen intrastromal préformé pour anomalies ou dystrophies cornéennes
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780030509.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784622

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2658564

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009524045

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/001745

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009109358

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2007784622

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007784622

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12377556

Country of ref document: US